Non-invasive markers for assessing liver fibrosis have been developed, and they are frequently used in clinical practice. They have been validated in different studies, and some were found to be highly accurate compared with liver biopsies which have always been used as the standard reference method for evaluating the accuracy of non-invasive methods
1
.The performance of a non-invasive diagnostic method is evaluated by calculation of the area under the receiver operator characteristic curve (AUROC) 2 .
Methods:
Non-invasive methods to assess histology in chronic liver disease include clinical symptoms and signs, routine laboratory tests, serum markers of fibrosis and inflammation, quantitative assays of liver function, and radiologic imaging studies. However, at present, none of these tests or markers alone is accurate or reliable in predicting histology, in particular, liver fibrosis. An ideal noninvasive diagnostic test for hepatic fibrosis should be simple, readily available, inexpensive, and accurate 3 .
I-Imaging:
Standard imaging techniques such as ultrasound, CT and MRI are able to detect advanced fibrosis when signs of portal hypertension are evident, but they cannot yet detect milder disease 4 .
1-Transient elastography (TE)
: is a non-invasive technique for assessment of liver fibrosis that was first described in the medical literature in 1999. The method is easy to learn, quick, results are available immediately, and a technical assistant may perform the procedure 4 .FibroScan measures the stiffness (or elasticity) of hepatic parenchyma using both ultrasound (5 MHz) and low-frequency (50 Hz) elastic waves produced by a specialized ultrasound vibrator applied to the body wall and coupled with 1D ultrasound imaging that measures the propagation speed of a wave using a pulse-echoultrasound 5 .
2-Contrast enhanced ultrasonographic imaging (CEUS):
uses intravenous administration of gas -filled microbubbles to enhance vascular signals and measure blood flow transit. Diminished hepatic vein transit time correlates with worsening liver disease 6 .
3-Acoustic radiation force impulse (ARFI):
combines conventional unltrasonographyof the liver with evaluation of local liver stiffness. As regions of evaluation can be chosen using ultrasound, ARFI allows operator avoidance of anatomical obstacles, e.g. large blood vessels 7 . Importantly, in contrast to FibroScan, liver steatosis had no statistical influence on ARFI results 8 . 
4-Magnetic

37
. 12-The GP model: it includes globulin level and platelets count. It predicts significant fibrosis in patients with chronic hepatitis B. This newly designed noninvasive marker must be evaluated in different populations before common use 38 .
13-The Lok index:
is an evolution of the APRI combining platelet count, INR and AST/ALT ratio. This index uses two cut-off values: 0.2 to rule out cirrhosis and 0.5 to confirm cirrhosis, whereas values between these cut-offs are considered indeterminate 39 . 14-The Proteomics based tests: assess patterns of protein or glycoprotein by mass spectroscopy using serum samples. Callewaert et al. developed tests based on the altered Nglycosylation of total serum protein (GlycoCirrhoTest and GlycoFibroTest), which could be both cost-effective and could rapidly determine a signature profile for nglycans 40 . 
Limitations
